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INTRODUCTION:  Primary  hepatic  lymphoma  is a rare  malignancy  which  misdiagnosis  and  mistreatment  is
very  frequent.  Differential  diagnosis  of  the  hepatic  lesion,  based  on  the noninvolvement  of blood  vessels,
includes:  fatty  inﬁltration,  cirrhosis,  amyloid  inﬁltration,  primary  hepatomas,  and  metastatic  neoplasms.
PRESENTATION  OF  CASE:  We  describe  a  case  of a 69-year-old  man  who  presented  with 15%  weight  loss
and  general  fatigue  over  the  previous  9 months.  Physical  examination  revealed  hepatomegaly  without
lymphadenopathy  or splenomegaly.  Magnetic  resonance  imaging  showed  a 13  cm × 9 cm  ×  11  cm  tumor
on  the  right  liver  associated  with  normal  levels  of alpha-fetoprotein  (AFP)  and carcinoembryonic  antigen
(CEA).  After  two negatives  ultrasonography-guided  needle  liver  biopsies,  the  third  one showed  diffuse
inﬁltration  of  large  sized  lymphoid  cells.  Immunohistochemical  ﬁndings  demonstrated  the  B-lymphocyte
lineage  of  the  tumor.  The  patient  received  R-CHOP  therapy  (cyclophosphamide,  doxorubicin,  vincristine,
prednisone,  and  rituximab)  with  good  response.
DISCUSSION: It  is important  to  recognize  PHL  because  it  responds  favorably  to chemotherapy  and  may
have  a  better  prognosis  than  hepatocellular  carcinoma  or metastatic  disease  of the  liver.  When  imaging
ﬁndings  on CT  scans  and  MRI  are  nonspeciﬁc,  a biopsy  is needed  not  only  for a  deﬁnitive  diagnosis  but
also  for  identifying  the  immunophenotype  of the  PHL.  This  type  of lesion  is  highly  chemosensitive  and
early  aggressive  chemotherapy  may  result  in  sustained  remission.
CONCLUSION: This  case  emphasizes  the  importance  of  effective  recognition  of PHL considering  its good
response  to  chemotherapy  and  the  possibility  of sustained  remission  if early  aggressive  treatment  is
implemented.
013 T© 2
. Introduction
Primary hepatic lymphoma (PHL) is a tumor conﬁned to the
iver without evidence of lymphomatous involvement of spleen,
ymph nodes, bone marrow or other lymphoid structures.1 PHL
s a very rare malignancy, and constitutes about 0.016% of all
ases of non-Hodgkin’s lymphoma.2 Most patients are treated with
hemotherapy, using different combinations of drugs.3 However,
ptimal therapy is still unclear and the outcomes are uncertain. The
ajority of PHL cases originate from B cells, and T-cell lymphoma
s less common.3 Misdiagnosis is frequent and cases of unnecessary
esection have been reported.2 The purpose of this case report is to
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describe a case of PHL and emphasize the importance of an accurate
diagnosis before implementing a therapeutic plan.
2.  Case presentation
Written informed consent was obtained from the patient
for publication of this case report and accompanying images.
In October 2011, a 69-year-old white man  presented with 15%
weight loss (22 kg), mental confusion, nocturnal fever, difﬁculty
in ambulation, limb weakness and general fatigue experienced
over the previous 9 months. Physical examination revealed hepa-
tomegaly, palpable 3 cm below the right costal margin, without
lymphadenopathy or splenomegaly.
2.1. Investigation
The results of the complete blood count were normal apart from
Open access under CC BY-NC-SA license. mild leukocytosis (white blood cell count: 13,340/L). The results
of liver function tests were aspartate aminotransferase (AST):
58 U/L, alanine aminotransferase (ALT): 130 U/L, gamma-glutamyl
transferase (GGT): 305 U/L, alkaline phosphatase (ALP): 601 U/L,
s Ltd. Open access under CC BY-NC-SA license. 
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big. 1. (a) Axial T1-weighted MRI, showing a hypoattenuating lesion, with a centra
reatment.
otal bilirubin (TB): 0.7 mg/dL and albumin: 3.4 g/dL. Lactate dehy-
rogenase (LDH) level was found to be 2648 U/L. Results of serologic
ests for hepatitis B virus, hepatitis C virus, human immunodeﬁ-
iency virus, and human T-lymphotropic virus-1 were negative.
AN and VDRL were negative. Tumor markers levels are described
s follows: carcinoembryonic antigen (CEA): 0.3 ng/mL, carbohy-
rate antigen 19–9 (CA 19.9): 7.0 U/mL, and alpha-fetoprotein
AFP): 4.58 ng/mL.
Magnetic resonance imaging (MRI) ﬁndings showed
 hypointense area on T1-weighted images sized of
3 cm × 9 cm × 11 cm,  and hyperintense on T2-weighted images
Fig. 1a). There was no mediastinal lymphadenopathy or brain
nvolvement on CT scan.
Two ultrasonography-guided needle liver biopsies were found
egative and the third one showed diffuse inﬁltration of large sized
ymphoid cells. Immunohistochemistry (Fig. 2): positive CD45-LCA,
ositive CD20; positive Ki67 in 80% of atypical cells; CD99 positive;
imentin positive. CD3, CD15, CD30, ACT, CK, CRO, DES, HMB45,
nd S100 were all negative. The diagnosis of primary large cells
on-Hodgkin B-cell lymphoma was made.
Bone marrow aspiration and biopsy examination showed no
vidence of diffuse large B-cell lymphoma.
.2. Treatment
The patient received R-CHOP treatment (cyclophosphamide,
oxorubicin, vincristine, prednisone, and rituximab) in 8 cycles
hroughout 12 months. Two sessions of radiotherapy were also
mplemented.
.3. Outcome and follow-up
In this case report, the patient showed a good response to treat-
ent with mild side effects. After 6 months, the lesion decreased
n size to 7 cm × 5 cm (Fig. 1b). After 24 months of follow-up, the
atient remained asymptomatic. However, imaging studies have
hown the persistence of a small calciﬁed lesion of 3 cm × 1.5 cm
Fig. 1c). The patient has been regularly seen in an outpatient facil-
ty.
. Discussion
This case highlights several important points. Although rare,
t is important to recognize PHL because it responds favorably to
hemotherapy and may  have a better prognosis than hepatocellular
arcinoma or metastatic disease of the liver. The differential diagno-
is should include primary hepatomas and metastatic neoplasms.
hen imaging ﬁndings on CT scans and MRI  are nonspeciﬁc, a
iopsy is needed not only for a deﬁnitive diagnosis but also for of low intensity indicating necrosis. Images 6 months (b) and 12 months (c) after
identifying the immunophenotype of the PHL. This type of lesion
is highly chemosensitive and early aggressive chemotherapy may
result in sustained remission.4
PHL is more frequent in men  and the usual age at presentation is
around 50 years. Presentations vary from the incidental discovery
of hepatic abnormalities in asymptomatic patients to onset of ful-
minant hepatic failure with rapid progression of encephalopathy
to coma and death. Symptoms are usually nonspeciﬁc, and include
right upper quadrant and epigastric pain, fatigue, weight loss, fever,
anorexia, and nausea. Hepatomegaly is very common, and jaundice
may  be found on physical examination.5
PHL can be subdivided into nodular or diffuse types according to
the presence of liver inﬁltration. Most PHL corresponds to a larger
cell type and demonstrates a B-cell immunophenotype. Other his-
tologic subtypes of PHL include high-grade tumors (lymphoblastic
and Burkett lymphoma, 17%), follicular lymphoma (4%), diffuse
histiocytic lymphoma (5%), lymphoma of the mucosa-associated
lymphoid tissue type, anaplastic large-cell lymphoma, mantle cell
lymphoma, and T- cell-rich B-cell lymphoma.5
The diagnosis of PHL still remains a challenge. The misdiag-
nosis is common and many times is made on histology of the
surgical specimen. Because of the presence of a large area of necro-
sis, the ﬁne needle tumor biopsy is frequently negative. In the
present case, we  achieved the ﬁnal diagnosis after two previous
negative biopsies. During the procedure one should be careful to
guide the needle toward an area without necrosis in order to get
a representative sample of the tumor. We  remark that patients
with PHL typically have abnormal liver function tests, with ele-
vation of LDH and ALP. Elevated LDH, with normal AFP and CEA,
remains a valuable biologic feature,5 as we have found in our
patient.
On ultrasound, PHL lesions are hypoechoic comparing to nor-
mal  liver. Imaging by CT shows hypoattenuating lesions and MRI
enhancement after contrast. Findings on MRI  are variable; however,
a few authors have described hypointense T1-weighted images and
hyperintense T2-weighted images.2–7
For PHL diagnosis, tumor must be conﬁned to liver, without
involvement of spleen, lymph nodes, bone marrow, or other lym-
phoid structures.5 Most patients are treated with chemotherapy,
with some physicians employing a multimodality approach that
also incorporates surgery and radiotherapy.2,5 The standard treat-
ment for patients with diffuse large B-cell lymphoma is CHOP.
The addition of rituximab, a chimeric monoclonal antibody, to
the CHOP regimen, augments the complete response rate and
prolongs event free and overall survival in patients with diffuse
large B-cell lymphoma, without a clinically signiﬁcant increase in
toxicity.4–8
Poor prognostic features include advanced age, constitutional
symptoms, bulky disease, unfavorable histologic subtype, elevated
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Fig. 2. Histopathology of the liver biopsy shows (a) normal hepatocytes and tumor cells (H&E, 100×) and (b) inﬁltration of large lymphoid cells (H&E, 400×), (c) positive
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3D45-LCA (100×), (d) positive cytokeratin in normal hepatocytes (100×), (e) positi
evels of LDH and a high proliferation rate, cirrhosis, and comorbid
onditions.6–8
. Conclusion
PHL should be considered as a diagnosis in cases of space
ccupying liver lesions with normal levels of AFP and CEA. If
he clinical picture is suspicious for PHL, a liver biopsy should
e obtained. PHL is treatable and overall survival has improved
or these patients with new therapeutic drugs such as ritux-
mab.
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57 (400×) and (f) positive CD20 (400×).
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